Skip to content

Independent Reserve becomes first Australian cryptocurrency exchange licensed in Singapore – Yahoo Finance

SYDNEY, Oct. 1, 2021 /PRNewswire/ — Cryptocurrency exchange Independent Reserve has today received approval for a Major Payment Institution Licence in Singapore, making it the first and only Australian virtual asset service provider available to retail and institutional investors in Singapore.
The approval was granted following a rigorous review of Independent Reserve by the local regulator, the Monetary Authority of Singapore, focused on customer protection mechanisms, transaction screening and compliance structures, as well as information technology services.
CEO Adrian Przelozny said he was delighted to receive the approval and proud that an Australian company had been selected, beating over 170 global exchanges to receive the coveted licence. He added Singapore's well-regulated environment would allay investor protection concerns around the safe custody of assets, KYC requirements, and market manipulation – making it easier to provide cryptocurrency services to retail and institutional investors that wish to trade digital assets.
"A well-regulated environment will benefit both investors and crypto industry stakeholders. With tailormade rules for the crypto industry, Singapore has the clearest and most detailed licensing requirements of any jurisdiction in Asia. And now, Independent Reserve is one of the first fully licensed crypto exchanges available to Singaporeans, enabling them to quickly and securely use their SGD to get in and out of crypto," he said.
"There are real opportunities for Australia to learn from Singapore's thorough approach to crypto industry licensing. Currently, there are no custodian requirements for digital asset exchanges in Australia. We'd like to see, and have been pushing for, appropriate legislation to be introduced locally that will support the industry and provide protection for investors," he said.
Established in Australia in 2013, Independent Reserve embarked on its international expansion plans in late 2019, setting up its first overseas operations in Singapore to provide digital asset exchange and OTC trading services to people and institutions.
Independent Reserve provides SGD, AUD, USD and NZD fiat-to-crypto trading pairs. The licence is a major step forward for individuals and companies in Singapore looking for an easy and trusted onramp into cryptocurrency.
ABOUT INDEPENDENT RESERVE
Established in 2013, Independent Reserve is Australia's most trusted cryptocurrency order book exchange and OTC trading desk. Over 200,000 customers from Singapore, Australia and New Zealand trust Independent Reserve to easily buy and sell Bitcoin, Ethereum, XRP and other major cryptocurrencies. Independent Reserve offers a range of innovative features, including AutoTrader, OTC trading desk, API integration and world-class security.
ABOUT THE MAJOR PAYMENT INSTITUTION LICENCE
The Monetary Authority of Singapore licensure approval was granted under the Payment Services Act for Independent Reserve to operate as a regulated provider for Digital Payment Token Services.
SOURCE Independent Reserve
Apotex Inc. is conducting a voluntary nationwide recall of one lot of Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) from wholesalers, distributors, retailers, pharmacies, and consumers. The identified lot is being recalled out of an abundance of caution due to a highly detectable defect of one placebo pill (green) in place of a birth control pill (white). This product is manufactured by a 3rd party source, Laboratorios LEON FARMA, S.A. Spain.
Readers hoping to buy Perenti Global Limited ( ASX:PRN ) for its dividend will need to make their move shortly, as the…
AUD/USD Current Price: 0.7229 Chinese data was mixed, with the manufacturing PMI contracting in September. Soaring gold prices helped the aussie to post gains vs its American rival. AUD/USD could extend its advance on a clear break above a Fibonacci resistance level. The AUD/USD pair recovered most of the ground lost on Wednesday, ending the day at around 0.7230. Despite a sharp slide in US equities and persistent demand for the American currency, the pair got to advance on the back of soaring g
You've may have thought, at one time or another, about making a big push and saving as much as you can in one month — but what about saving $1,000? Even though it's an amount that may seem…
Long-term care insurance is designed to help Americans afford the healthcare services some need, whether that be near the end of their lives or years earlier than that. The exact details of your policy will depend on a number of … Continue reading → The post Nationwide Long-Term Care Insurance Review appeared first on SmartAsset Blog.
Still earning peanuts in your savings account? These 3 income stocks might help.
Shares of electric vehicle maker Nio (NYSE: NIO) rose 3% Friday morning before losing ground as the day progressed, trading down just about 0.5% as of 1:40 p.m. today. The weakness in the EV stock's price is surprising given that Nio reached a milestone and reported solid delivery numbers for September today, even topping its own projections. Nio delivered a record number of 10,628 vehicles in total in September, up 125.7% year over year.
Down at the bottom, investors get into the market for the same reason: to make money. And that drive will push them to find an equity strategy that ensures solid returns, no matter what the markets do. The conventional wisdom will suggest two such strategies: buying stocks when they’re priced low, and getting into dividend stocks. The first is self-explanatory. Low priced stocks have more room for share appreciation, and Wall Street’s analysts are always on the lookout for solid buys with a low
Yahoo Finance Live chats with investing pioneer Alec Gores of The Group about his latest playing on the future of the automobile.
In this article, we discuss the 15 stocks Cathie Wood is dumping. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood is Dumping These 5 Stocks. The portfolio value of ARK Investment Management, the New York-based hedge fund managed by Cathie Wood, has increased from over $50 billion […]
By Geoffrey Smith
Shares of solar energy stock SunPower (NASDAQ: SPWR) jumped as much as 12.3% in trading on Friday after announcing that it will join the S&P MidCap 400 next week. SunPower will replace Cimarex Energy, which is being acquired by Cabot Oil & Gas, in the index. The reason shares often jump when announcements like this are made is because funds that follow an index like the S&P MidCap 400 will need to buy shares to get exposure to SunPower stock.
Vaccine manufacturer stocks slumped Friday after Merck announced promising results for a Covid-19 oral pill.
Merck shares jumped as much as 12.3% and hit their highest level since February 2020 after data showed the company's pill molnupiravir https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19. At the same time, shares of vaccine makers such as Moderna Inc, Pfizer Inc and partner BioNTech SE were hit, with some analysts saying the promise of an oral drug that can be taken at home could change the public perception of risks associated with COVID-19. "We see modest perceived headwind to vaccine stocks such as MRNA (Moderna) if the market thinks people will be less afraid of COVID-19 and less inclined to get vaccines, if there is a simple pill that can treat COVID-19," Jefferies analyst Michael Yee said in a client note.
A supplier of chipmaking equipment predicts a decade-long period of growing semiconductor production.
Hundreds of Chinese companies are listed on U.S. markets. But which are the best Chinese stocks to buy or watch right now? Weibo, Sohu, Nio, BYD Co. and Li Auto. China is the world's most-populous nation and the second-largest economy with a booming urban middle class and amazing entrepreneurial activity.
Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ: AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech's shares are taking flight today in response to a successful interim analysis for Merck's oral COVID-19 pill, molnupiravir, in a late-stage trial. Atea, for its part, is also trialing an oral COVID-19 medication, known as AT-527, with a broadly similar mechanism of action (they both interfere with viral replication).
A reader has just written in urging me to take another look at Roth IRAs. This follows my previous column, where I said I was wary of them, partly because I figured I’ll be paying a lower tax rate in retirement than I am when I’m working. “The tax rate is not the issue, it’s the amount of tax you will be paying,” he reminds me.
Friday's bounce is only day one of a market rally attempt. It's still a correction for now. Here's what to do.
Steel companies are benefiting from surging demand and prices, and the future looks bright. Yet, the stocks remain among Wall Street’s cheapest.

source

Leave a Reply

Your email address will not be published. Required fields are marked *